|
96
|
334
|
6y23A |
Ddr1 kinase autoinhibited by its juxtamembrane region |
|
134
|
573
|
6kbiA |
Crystal structure of erbb3 n418q mutant |
|
89
|
300
|
6jpeA |
Crystal structure of fgfr4 kinase domain with irreversible inhibitor 1 |
|
103
|
305
|
6xvjA |
Crystal structure of the kdr (vegfr2) kinase domain in complex with a type-ii inhibitor |
|
97
|
306
|
6xv9A |
Crystal structure of the kinase domain of human c-kit in complex with a type-ii inhibitor |
|
98
|
303
|
6xvbA |
Crystal structure of the kinase domain of human c-kit with a cyclic imidate inhibitor covalently bound to cys788 |
|
99
|
303
|
6xvaA |
Crystal structure of the kinase domain of human c-kit in complex with a type-ii inhibitor bearing an acrylamide |
|
100
|
298
|
6xvkA |
Crystal structure of the kdr (vegfr2) kinase domain in complex with a type-ii inhibitor bearing an acrylamide |
|
39
|
318
|
6vwjA |
Leg region of the closed conformation of the human type 1 insulin-like growth factor receptor ectodomain in complex with human insulin-like growth factor ii |
|
109
|
457
|
6vwgA |
Head region of the open conformation of the human type 1 insulin-like growth factor receptor ectodomain in complex with human insulin-like growth factor ii. |
|
114
|
457
|
6vwiA |
Head region of the closed conformation of the human type 1 insulin-like growth factor receptor ectodomain in complex with human insulin-like growth factor ii. |
|
21
|
223
|
6vwhA |
Leg region of the open conformation of the human type 1 insulin-like growth factor receptor ectodomain in complex with human insulin-like growth factor ii. |
|
80
|
306
|
6vepE |
Human insulin in complex with the human insulin microreceptor in turn in complex with fv 83-7 |
|
3
|
16
|
6vepF |
Human insulin in complex with the human insulin microreceptor in turn in complex with fv 83-7 |
|
2
|
15
|
6veqF |
Con-ins g1 in complex with the human insulin microreceptor in turn in complex with fv 83-7 |
|
69
|
305
|
6veqE |
Con-ins g1 in complex with the human insulin microreceptor in turn in complex with fv 83-7 |
|
90
|
311
|
6pl4A |
Trk-a in complex with ligand 1 |
|
92
|
291
|
6in0A |
Crystal structure of epha3 in complex with 18-crown-6 |
|
91
|
299
|
6iupA |
Crystal structure of fgfr4 kinase domain in complex with compound 5 |
|
15
|
35
|
1iijA |
Solution structure of the neu/erbb-2 membrane spanning segment |
|
85
|
289
|
6nviA |
Fgfr4 complex with n-(3-chloro-2-((5-((2,6-dichloro-3,5-dimethoxybenzyl)oxy)pyrimidin-2-yl)amino)-5-fluorophenyl)acrylamide |
|
88
|
289
|
6nvhA |
Fgfr4 complex with n-(2-((5-((2,6-dichloro-3,5-dimethoxybenzyl)oxy)pyrimidin-2-yl)amino)-3-methylphenyl)acrylamide |
|
83
|
303
|
6nvlA |
Fgfr1 complex with n-(2-((5-((2,6-dichloro-3,5-dimethoxybenzyl)oxy)pyrimidin-2-yl)amino)-3-methylphenyl)acrylamide |
|
86
|
290
|
6nvjA |
Fgfr4 complex with n-(2-((5-((2,6-dichloro-3,5-dimethoxybenzyl)oxy)pyrimidin-2-yl)amino)-3-fluorophenyl)acrylamide |
|
81
|
289
|
6nvkA |
Fgfr4 complex with blu-554, n-((3s,4s)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl)amino)tetrahydro-2h-pyran-4-yl)acrylamide |
|
85
|
290
|
6nvgA |
Fgfr4 complex with n-(3,5-dichloro-2-((5-((2,6-dichloro-3,5-dimethoxybenzyl)oxy)pyrimidin-2-yl)amino)phenyl)acrylamide |
|
0
|
9
|
1qr1C |
Poor binding of a her-2/neu epitope (gp2) to hla-a2.1 is due to a lack of interactions in the center of the peptide |
|
1
|
7
|
1uefD |
Crystal structure of dok1 ptb domain complex |
|
0
|
7
|
5ex3D |
Crystal structure of human smyd3 in complex with a vegfr1 peptide |
|
99
|
307
|
6mweA |
Crystal structure of tie2 in complex with decipera compound dp1919 |
|
30
|
294
|
6hn4E |
Leucine-zippered human insulin receptor ectodomain with single bound insulin - "lower" membrane-proximal part |
|
118
|
594
|
6hn5E |
Leucine-zippered human insulin receptor ectodomain with single bound insulin - "upper" membrane-distal part |
|
92
|
303
|
6finA |
Ddr1, 3-[(3-cyclopropyl-1,2,4-oxadiazol-5-yl)methyl]-8-(1h-indazole-5-carbonyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one, 1.670a, p1211, rfree=22.8% |
|
86
|
299
|
6ferA |
Crystal structure of human ddr2 kinase in complex with 2-[4,5-difluoro-2-oxo-1'-(1h-pyrazolo[3,4-b]pyridine-5-carbonyl)spiro[indole-3,4'-piperidine]-1-yl]-n-(2,2,2-trifluoroethyl)acetamide |
|
94
|
303
|
6fimA |
Ddr1, 2-[8-(1h-indazole-5-carbonyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]-n-methylacetamide, 1.440a, p1211, rfree=24.1% |
|
95
|
307
|
6fiqA |
Ddr1, 1-(1h-indazole-5-carbonyl)-5'-methoxy-1'-[2-oxo-2-[(2s)-2-(trifluoromethyl)pyrrolidin-1-yl]ethyl]spiro[piperidine-4,3'-pyrrolo[3,2-b]pyridine]-2'-one, 1.790a, p212121, rfree=23.8% |
|
93
|
301
|
6fexA |
Ddr1, 2-[4-bromo-2-oxo-1'-(1h-pyrazolo[4,3-b]pyridine-5-carbonyl)spiro[indole-3,4'-piperidine]-1-yl]-n-(2,2,2-trifluoroethyl)acetamide, 1.291a, p212121, rfree=17.4% |
|
95
|
303
|
6filA |
Ddr1, 2-[8-(1h-indazole-5-carbonyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]-n-methylacetamide, 1.730a, p212121, rfree=24.5% |
|
94
|
303
|
6fewA |
Ddr1, 2-[8-(1h-indazole-5-carbonyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]-n-methylacetamide, 1.440a, p1211, rfree=24.1% |
|
99
|
309
|
6fioA |
Ddr1, 2-[1'-(1h-indazole-5-carbonyl)-4-methyl-2-oxospiro[indole-3,4'-piperidine]-1-yl]-n-(2,2,2-trifluoroethyl)acetamide, 1.990a, p6522, rfree=27.7% |
|
92
|
309
|
6bsdA |
Ddr1 bound to dasatinib |
|
152
|
607
|
6bgtC |
Structure of trastuzumab fab mutant in complex with her2 extracellular domain |
|
91
|
309
|
6brjA |
Ddr1 bound to vx-680 |
|
85
|
302
|
6mzqA |
Tas-120 in reversible binding mode with fgfr1 |
|
137
|
618
|
6j71A |
Hua21-scfv in complex with the extracellular domain(ecd) of her2 |
|
83
|
302
|
6mzwA |
Tas-120 covalent complex with fgfr1 |
|
96
|
328
|
6il3A |
Crystal structure of the flt3 kinase bound to a small molecule inhibitor |
|
94
|
307
|
6mx8A |
Crystal structure of anaplastic lymphoma kinase (alk) bound by brigatinib |
|
91
|
477
|
6i04A |
Crystal structure of sema domain of the met receptor in complex with fab |
|
95
|
311
|
6hp9A |
Structure of the kinase domain of human ddr1 in complex with a 2-amino-2,3-dihydro-1h-indene-5-carboxamide-based inhibitor |
